All In Biotech

Drug Trial Radar · NCT05732805

A Clinical Study of BCD-217 (Nurulimab + Prolgolimab) Followed by Anti-PD-1 Compared to Anti-PD-1 Monotherapy as First-Line Treatment in Subjects With Unresectable/Metastatic Melanoma

A Double-Blind Placebo-Controlled Comparative Randomized Clinical Study of the Efficacy and Safety of BCD-217 (Nurulimab + Prolgolimab) Followed by Anti-PD-1 Compared to Anti-PD-1 Monotherapy as First-Line Treatment in Subjects With Unresectable/Metastatic Melanoma

Last checked: Nov 19, 2026Latest source record: Feb 27, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 270 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

270

Planned (sponsor's estimate)

Start

Aug 2, 2022

Primary completion

Jun 20, 2024

Study completion Jul 2025

Sponsor

Lead sponsor
BiocadIndustry
Sponsor type
Industry
First posted
Feb 17, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The aim of study is to investigate the efficacy, safety, immunogenicity, pharmacokinetics, and pharmacodynamics of BCD-217 followed by prolgolimab monotherapy versus prolgolimab monotherapy as first-line therapy in subjects with unresectable or metastatic melanoma.

Conditions

  • Melanoma
  • Melanoma (Skin)
  • Melanoma Stage III
  • Melanoma Stage IV
  • Melanoma Unresectable
  • Melanoma Metastatic
  • Melanoma Advanced

Interventions

  • BCD-217Biological

    Subject recieves BCD-217 0.2 mL/kg, which is equivalent to 1 mg/kg nurulimab + 3 mg/kg prolgolimab, as an intravenous infusion once every 3 weeks (Q3W) simultaneously with placebo, a total of 4 intravenous infusions. Beginning with the 5th infusion, subjects are switched to prolgolimab 1 mg/kg monotherapy once every 2 weeks (Q2W).

  • BCD-100Biological

    Subject recieves prolgolimab 3 mg/kg as an intravenous infusion once every 3 weeks (Q3W) simultaneously with placebo, a total of 4 intravenous infusions. Beginning with the 5th infusion, subjects are switched to prolgolimab 1 mg/kg monotherapy once every 2 weeks (Q2W).

  • PlaceboBiological

    Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free survivalTime frame: 24 months

Locations

63 sites in 3 countries. Site status is shown where the registry gives one.

  • Healthcare Institution "Bobruisk Interdistrict Oncological Dispensary"

    Babruysk, Belarus

  • Healthcare Institution "Brest Regional Oncological Dispensary"

    Brest, Belarus

  • Health care institution "Grodno University Clinic"

    Grodno, Belarus

  • Health Institution "Gomel Regional Clinical Oncology Center"

    Homyel, Belarus

  • State Institution "Republican Scientific and Practical Center of Oncology and Medical Radiology named after A.I. N.N. Alexandrov"

    Lesnoy, Belarus

  • Healthcare Institution "Minsk City Clinical Cancer Center"

    Minsk, Belarus

  • State Institution "Mogilev Regional Oncological Dispensary"

    Mogilev, Belarus

  • Healthcare Institution "Vitebsk Regional Clinical Oncology Center"

    Vitebsk, Belarus

  • Fortis Hospital

    Faridabad, India

  • Kasturba Medical College and Hospital

    Mangalore, India

  • TATA Memorial Hospital

    Mumbai, India

  • HealthCare Global Enterprises Ltd, NCHRI Cancer Center

    Nagpur, India

  • HealthCare Global Enterprises Ltd Manavata cancer Centre

    Nashik, India

  • Sankalp Superspeciality Hospital

    Nashik, India

  • All India Institute of Medical Science

    New Delhi, India

  • Deenanath Mangeshkar Hospital & Research Center

    Pune, India

  • PDEAS Ayurved Rugnalaya & Steriling Multispeciality Hospital

    Pune, India

  • Horizon Mulitispeciality Hospital

    Sangli, India

  • Shalby Hospital

    Surat, India

  • Kiran Multispeciality hospital &Research

    Sūrat, India

  • Arkhangelsk Clinical Oncology Dispensary

    Arkhangelsk, Russia

  • Regional State Budgetary Institution of Health Care "Altai Regional Oncological Dispensary"

    Barnaul, Russia

  • Limited Liability Company "EVIMED"

    Chelyabinsk, Russia

  • Private healthcare institution "Clinical hospital "RZD-Medicine" of the city of Chelyabinsk"

    Chelyabinsk, Russia

  • State budgetary healthcare institution Leningrad Regional Clinical Hospital

    Gatchina, Russia

  • State Autonomous Health Institution "Republican Clinical Oncology Dispensary of the Ministry of Health of the Republic of Tatarstan named after Professor M.Z. Sigal"

    Kazan', Russia

  • State budgetary health care institution "Kuzbass clinical oncological dispensary named after M.S. Rappoport"

    Kemerovo, Russia

  • Regional Goverment Budgetary Healthcare State "Kostroma Oncology Center"

    Kostroma, Russia

  • State Budgetary Institution of Healthcare "Leningrad Regional Clinical Oncological Dispensary named after V.I. L.D. Romana"

    Kuz'molovskiy, Russia

  • "Russian Cancer Research Center named after N.N. Blokhin "of the Ministry of Health of the Russian Federation

    Moscow, Russia

  • Branch of Hadassah Medical LTD Limited Liability Company

    Moscow, Russia

  • Federal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University)

    Moscow, Russia

  • Joint Stock Company "K31 City"

    Moscow, Russia

  • JSC "Medsi Group"

    Moscow, Russia

  • Moscow City Oncology Hospital No. 62

    Moscow, Russia

  • State budgetary health care institution of the city of Moscow "City Clinical Oncology Hospital No. 1 of the Department of Health of the City of Moscow"

    Moscow, Russia

  • State Budgetary Institution of Healthcare of the City of Moscow "Moscow Multidisciplinary Clinical Center "Kommunarka" of the Department of Health of the City of Moscow"

    Moscow, Russia

  • Nizhny Novgorod Region State Budgetary Healthcare Facility "Clinical Diagnostics Center"

    Nizhny Novgorod, Russia

  • LLC "DobroMed"

    Novosibirsk, Russia

  • State Budgetary Healthcare Institution "Novosibirsk Regional Clinical Oncology Center" of the Novosibirsk Region

    Novosibirsk, Russia

Showing 40 of 63 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.